OneMedNet Q3 Revenue Surges, But Liquidity Risks Unaddressed
Read source articleWhat happened
OneMedNet reported Q3 2026 revenue of $1.02 million, marking a 250% sequential increase from Q2 2026 and a 478% year-over-year jump from Q3 2025, signaling strong traction in its iRWD offering following the BEAM decommissioning. Despite this robust top-line growth, the absolute revenue remains sub-scale relative to the company's historical operating losses and cash burn. The press release reiterates Q4 2026 guidance but omits critical details on cash position, operating expenses, or profitability, leaving unresolved the going-concern and liquidity concerns that were prominent in earlier filings. The prior DeepValue master report, based on Q2 2025 data, highlighted acute liquidity constraints, Nasdaq noncompliance, and reliance on potentially dilutive financing, none of which are addressed by this update. While the revenue acceleration is encouraging, investors should treat the stock with caution until the company demonstrates sustained profitability and a strengthened balance sheet.
Implication
Investors should continue to view ONMD as a high-risk, speculative investment. The revenue growth is positive but does not yet meet the earlier threshold of two consecutive quarters above $1M in iRWD revenue, nor does it provide evidence of improved cash flow or resolution of going-concern issues. A wider margin of safety is warranted, and close monitoring of quarterly filings for balance sheet health and Nasdaq compliance updates is essential before any thesis upgrade.
Thesis delta
The SELL thesis remains intact; the Q3 2026 revenue spike is a step in the right direction but falls short of the two-consecutive-quarters >$1M iRWD revenue threshold that would support a shift to HOLD. No new information on liquidity, financing, or compliance is provided, so the original concerns about going concern and dilution risk persist.
Confidence
Medium-High